Ford and GM Near Financing Deal to Support First Brands Group During Bankruptcy 
Samsung Set to Begin HBM4 Production for Nvidia and AMD 
Embraer Targets Growth as Regional Jet Demand Surges Post-Pandemic 
Tesla Loses Ground in Europe as BYD Accelerates EV Market Share in 2025 
LVMH Succession Uncertainty Raises Governance Concerns Among Shareholders 
Hermès Menswear Marks Historic Transition as Véronique Nichanian Bids Farewell in Paris 
Baker Hughes Reports 11% Rise in Q4 Adjusted Profit Driven by LNG Demand 
SEC Drops Gemini Enforcement Case After Full Repayment to Earn Investors 
Micron to Expand Memory Chip Manufacturing Capacity in Singapore Amid Global Shortage 
Noble Corporation Secures $1.3 Billion in New Contracts, Strengthening Offshore Drilling Backlog 
Zijin Mining Shares Hit Record High on $4 Billion Allied Gold Acquisition 
California Governor Gavin Newsom Launches Review Into Alleged TikTok Content Suppression After U.S. Ownership Deal 
Delta Air Lines Operates Reduced Flight Schedule as Winter Storm Disrupts U.S. Travel 
NTSB Opens Investigation Into Waymo Robotaxis After School Bus Safety Violations in Texas 
Microsoft Wins Approval to Build 15 New Data Centers in Wisconsin 
ANTA Sports to Acquire Major Stake in Puma in €1.5 Billion Deal, Signaling Strategic Revival 
NEW YORK, May 16, 2017 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Eastern District of New York on behalf of investors who purchased Intra-Cellular Therapies, Inc. ("Intra-Cellular Therapies") (NASDAQ:ITCI) securities between August 12, 2014 and April 28, 2017.
Click here to learn about the case: http://www.wongesq.com/pslra-sa/intra-cellular-therapies-inc?wire=3. There is no cost or obligation to you.
According to the complaint, throughout the Class Period, the Company issued materially false and misleading statements and/or failed to disclose that: (1) findings related to toxicity in animals treated with lumateperone (ITI-007) were observed; (2) these findings posed an additional safety concern regarding lumateperone; (2) and as a result of the above, the Company’s public statements were materially false and misleading at all relevant times. On August 4, 2016, the Company’s CEO Sharon Mates touted the “efficacy and safety of ITI-007 for the treatment of schizophrenia.” Then on May 1, 2017, Intra-Cellular disclosed that the U.S. Food and Drug Administration requested information from the Company in order to verify whether or not there are safety risks associated with long term exposure of ITI-007 to patients.
If you suffered a loss in Intra-Cellular Therapies you have until July 11, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra-sa/intra-cellular-therapies-inc?wire=3.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
